Evidence map›Paper›PMID 23184636›Full record

ArticleHepatology (Baltimore, Md.)2013

Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis.

Richy C Y Chen, Phornnop Naiyanetr, Shang-An Shu, Jinjun Wang, Guo-Xiang Yang, Thomas P Kenny, Kathryn C Guggenheim, Jeffrey D Butler, Christopher Bowlus, Mi-Hua Tao and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Animal Models of Autoimmune Liver Diseases: a Comprehensive Review.Clinical reviews in allergy & immunology · 2020
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.Journal of managed care & specialty pharmacy · 2016
    Review
  16. Review
  17. Environmental Basis of Autoimmunity.Clinical reviews in allergy & immunology · 2016
    Review
  18. Review
  19. Review
  20. IL-35 and Autoimmunity: a Comprehensive Perspective.Clinical reviews in allergy & immunology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 5 countries.

Richy C Y ChenDivision of Rheumatology/Allergy and Clinical Immunology, University of California, Davis, CA 95616, USA.
Phornnop Naiyanetr
Shang-An Shu
Jinjun Wang
Guo-Xiang Yang
Thomas P Kenny
Kathryn C Guggenheim
Jeffrey D Butler
Christopher Bowlus
Mi-Hua Tao
Mark J Kurth
Aftab A Ansari
Marshall Kaplan
Ross L Coppel
Ana Lleo
M Eric Gershwin
Patrick S C Leung
University of California, Davis · USEmory University · USHumanitas University · ITInstitute of Biomedical Sciences, Academia Sinica · TWMahidol University · THMonash University · AUTufts University · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
XENOBIOTICS AND PRIMARY BILIARY CIRRHOSISR01DK067003 · NIDDK · UNIVERSITY OF CALIFORNIA DAVIS · PI GERSHWIN, MERRILL E · 2003 to 2017
$4.4M
MECHANISMS AND PATHOGENESIS OF PRIMARY BILIARY CIRRHOSISR37DK039588 · NIDDK · UNIVERSITY OF CALIFORNIA DAVIS · PI GERSHWIN, MERRILL E · 2001 to 2010
$3.5M
MECHANISMS AND PATHOGENESIS OF PRIMARY BILIARY CIRRHOSISR01DK039588 · NIDDK · UNIVERSITY OF CALIFORNIA DAVIS · PI GERSHWIN, MERRILL E · 1988 to 2015
$2.0M
NCI NIH HHS P30 CA093373NIDDK NIH HHS DK067003NIDDK NIH HHS DK39588NIDDK NIH HHS R01 DK039588NIDDK NIH HHS R01 DK067003NIDDK NIH HHS R37 DK039588
6 · The paper itself

Abstract

unlabelledAntimitochondrial antibodies (AMAs) directed against the lipoyl domain of the E2 subunit of pyruvate dehydrogenase (PDC-E2) are detected in 95% of patients with primary biliary cirrhosis (PBC) and are present before the onset of clinical disease. The recent demonstration that AMAs recognize xenobiotic modified PDC-E2 with higher titers than native PDC-E2 raises the possibility that the earliest events involved in loss of tolerance are related to xenobiotic modification. We hypothesized that reactivity to such xenobiotics would be predominantly immunoglobulin M (IgM) and using sera from a large cohort of PBC patients and controls (n = 516), we examined in detail sera reactivity against either 6,8-bis(acetylthio) octanoic acid (SAc)-conjugated bovine serum albumin (BSA), recombinant PDC-E2 (rPDC-E2) or BSA alone. Further, we also defined the relative specificity to the SAc moiety using inhibition enzyme-linked immunosorbent assay (ELISA); SAc conjugate and rPDC-E2-specific affinity-purified antibodies were also examined for antigen specificity, isotype, and crossreactivity. Reactivity to SAc conjugates is predominantly IgM; such reactivity reflects a footprint of previous xenobiotic exposure. Indeed, this observation is supported by both direct binding, crossreactivity, and inhibition studies. In both early and late-stage PBC, the predominant Ig isotype to SAc is IgM, with titers higher with advanced stage disease. We also note that there was a higher level of IgM reactivity to SAc than to rPDC-E2 in early-stage versus late-stage PBC. Interestingly, this finding is particularly significant in light of the structural similarity between SAc and the reduced form of lipoic acid, a step which is similar to the normal physiological oxidation of lipoic acid.

conclusionSpecific modifications of the disulfide bond within the lipoic-acid-conjugated PDC-E2 moiety, i.e., by an electrophilic agent renders PDC-E2 immunogenic in a genetically susceptible host.

Indexed as

Antibodies, Anti-IdiotypicAntibody SpecificityAutoantigensCase-Control StudiesCholangitis, SclerosingDihydrolipoyllysine-Residue AcetyltransferaseHepatitis, AutoimmuneHumansImmunoglobulin MLiver Cirrhosis, BiliaryMitochondriaMitochondrial ProteinsRecombinant ProteinsSerum Albumin, BovineXenobioticsAntibodies, Anti-IdiotypicAutoantigensDihydrolipoyllysine-Residue AcetyltransferaseDLAT protein, humanImmunoglobulin MMitochondrial ProteinsRecombinant ProteinsSerum Albumin, BovineXenobiotics

Identifiers

PMID23184636
PMCPMC3601563
OpenAlexW1981816053

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.